If single-use systems can continue to evolve and meet the industry’s needs of cost savings, improved profitability and support of complex therapies, they are likely to become fully standardized, ultimately enhancing access to cutting-edge biotherapies and contributing to the broader advancement of biopharma manufacturing.
